Cannara Biotech Inc.
Research Cannara Biotech Inc. (8CB0) on Bullrun: valuation model: 41.4% undervalued, market cap EUR 86.93M, P/E 12.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8CB0
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Valuation signal41.4% undervalued
- Market capEUR 86.93M
- P/E12.6
- Financial periodQ1 2026
- RevenueEUR 27.18M
- Net incomeEUR 1.66M
- Free cash flow-EUR 286.30K
- Gross margin42.9%
Valuation Snapshot
Bullrun's latest valuation model marks Cannara Biotech Inc. as 41.4% undervalued; latest market cap is EUR 86.93M; P/E is 12.6.
About Cannara Biotech Inc.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc.
Frequently asked questions
Is Cannara Biotech Inc. overvalued or undervalued?
Bullrun's valuation model currently marks Cannara Biotech Inc. as 41.4% undervalued.
What is Cannara Biotech Inc.'s market cap?
Cannara Biotech Inc.'s market capitalization is EUR 86.93M.
What is Cannara Biotech Inc.'s P/E ratio?
Cannara Biotech Inc.'s price-to-earnings (P/E) ratio is 12.6.
What does Cannara Biotech Inc. do?
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations.